Sanofi avoided a fine from European Union antitrust regulators. The company accepted a settlement to end an investigation into its marketing practices. This resolves a probe into an alleged campaign that disparaged a rival flu vaccine. The investigation focused on claims that Sanofi portrayed the Fluad vaccine, marketed by CSL Seqirus, as inferior to its own Efluelda vaccine. According to the European Commission, this misleading communication campaign primarily targeted health care professionals in Germany and France. The regulator noted that Sanofi holds a dominant position in the markets of both countries. To settle the matter, Sanofi committed to running a corrective communication campaign to rectify its possible disparaging behavior. It also agreed to refrain from such conduct in the future. Teresa Riberta, the European Commission executive vice president for Clean, Just and Competitive Transition, announced the resolution. The agreement is legally binding.